Determination of potential adjuvant systemic therapy benefits for patients with resected cutaneous melanomas

Mayo Clinic Proceedings

Volumn 77, Issue 9, 2002, Pages 913-917

  Thomé, Stephan D ^a   Loprinzi, Charles L ^a   Heldebrant, Michael P ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERFERON;

ARTICLE; CANCER ADJUVANT THERAPY; CANCER IMMUNOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; DRUG MEGADOSE; HUMAN; INFORMED CONSENT; MAJOR CLINICAL STUDY; MELANOMA; PROGNOSIS; RISK BENEFIT ANALYSIS; SKIN CANCER;

EID: 0036725295     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0025-6196(11)62258-1     Document Type: Article

References (16)

1. A new American Joint Committee on Cancer staging system for cutaneous melanoma
2. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma
3. Prognostic factors analysis of 17,600 melanoma patients: Validation of the American Joint Committee on Cancer melanoma staging system
4. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group Trial EST 1684
5. Efficacy, safety, and risk-benefit analysis of adjuvant interferon alfa-2b in melanoma
6. High- and low-dose interferon alfa-2b in high-risk melanoma: First analysis of intergroup trial E1690/S9111/C9190
7. High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: Results of intergroup trial E1694/S9512/C509801
8. Adjuvant therapy of high-risk resected melanoma: Relapse-free and overall survival effects of high-dose interferon alpha-2b in randomized controlled multicenter trials E1684 and E2696 and Intergroup Trials E1690 and E1694
9. High-dose interferon alfa-2b does not diminish antibody response to GM2 vaccination in patients with resected melanoma: Results of the multicenter Eastern Cooperative Oncology Group Phase II Trial E2696
10. Interferon alfa therapy for malignant melanoma: A systematic review of randomized controlled trials
11. The EORTC Melanoma Group: A comprehensive melanoma research programme by clinicians and scientists
12. Understanding the utility of adjuvant systemic therapy for primary breast cancer
13. An informatics system designed to assist in making breast cancer adjuvant therapy decisions
14. Results of a randomized trial of a computerized decision aid "Adjuvant!" to present tailored prognostic information to stage I-III breast cancer patients
15. Evaluation of impact of communication tool generated by the computer program, "Adjuvant!" on patients with early breast cancer and their doctors